Reading RNXT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track RNXT free→Reading RNXT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track RNXT free→QuarterlyIQ Insights · RNXT
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 14, 2026, RenovoRx, Inc. (the “Company”) issued a press release announcing its financial results as of and for the quarter ended March 31, 2026. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Results of Operations and Financial Condition. On March 30, 2026, RenovoRx, Inc. (the “Company”) issued a press release announcing its financial results as of and for the fiscal year ended December 31, 2025. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. On March 24, 2026, the board of directors (the “Board”) of RenovoRx, Inc., a Delaware corporation (the “Company”), formally appointed Ramtin Agah, M.D., Chief Medical Officer and Chairman of the Board of the Company, to the newly created position of Executive Chairman, effective February 27, 2026. In connection with his roles as Chief Medical Office…
Unregistered Sales of Equity Securities. To the extent required by
Entry into a Material Definitive Agreement. On March 17, 2026, RenovoRx, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) in connection with a private placement offering by the Company (the “Offering”) to 15 accredited investors or qualified institutional buyers (the “Investors”), five of whom are directors, officers or employees of the Company (the “Insiders”) and the remaining are non-affiliated institutional in…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. On February 3, 2026, Ronald B. Kocak notified the board of directors (the “Board”) of RenovoRx, Inc., a Delaware corporation (the “Company”), his intent to resign from his position as Principal Accounting Officer of the Company, effective as of the close of business on February 3, 2026. The circumstances of his resignation do not constitute “Good Re…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On December 31, 2025, RenovoRx, Inc., a Delaware corporation (the “Company”) received a deficiency notice from The Nasdaq Stock Market (“Nasdaq”) informing the Company that its common stock, par value $0.0001 per share (the “Common Stock”), failed to comply with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) based up…
Entry into a Material Definitive Agreement. On November 14, 2025, RenovoRx, Inc., a Delaware corporation (the “Company”), and JonesTrading Institutional Services LLC (the “Agent”) entered into a Capital on Demand™ Sales Agreement (the “Sales Agreement”), pursuant to which the Company may issue and sell, from time to time, up to $3,723,029 in aggregate principal amount of shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share, through or to the Agent, as the Company’s…
Results of Operations and Financial Condition. On November 13, 2025, RenovoRx, Inc. (the “Company”) issued a press release announcing its financial results as of and for the quarter ended September 30, 2025. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Results of Operations and Financial Condition. On August 14, 2025, RenovoRx, Inc. (the “Company”) issued a press release announcing its financial results as of and for the quarter ended June 30, 2025. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Results of Operations and Financial Condition. On May 15, 2025, RenovoRx, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2025. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Results of Operations and Financial Condition. On April 1, 2025, RenovoRx, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2024. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Entry into a Material Definitive Agreement. On February 6, 2025, RenovoRx, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) by and between the Company and Titan Partners Group LLC, a division of American Capital Partners, LLC, as the sole bookrunner (the “Underwriter”). Pursuant to the Underwriting Agreement, the Company agreed to sell to the Underwriter, in a firm commitment underwritten public offering (the “Offering”), 11,5…
Importance-ranked changes since the prior daily snapshot.
Valuation label changed from 'full' to 'expensive'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.